260 related articles for article (PubMed ID: 37468622)
1. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming.
Juul NH; Yoon JK; Martinez MC; Rishi N; Kazadaeva YI; Morri M; Neff NF; Trope WL; Shrager JB; Sinha R; Desai TJ
Nature; 2023 Jul; 619(7971):860-867. PubMed ID: 37468622
[TBL] [Abstract][Full Text] [Related]
2. Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.
Yang M; Shen H; Flodby P; Koss MD; Bassiouni R; Liu Y; Jashashvili T; Neely A; Ogbolu E; Castillo J; Stueve TR; Mullen DJ; Ryan AL; Carpten J; Castaldi A; Wallace WD; Zhou B; Borok Z; Marconett CN
Cell Rep; 2023 Dec; 42(12):113286. PubMed ID: 37995179
[TBL] [Abstract][Full Text] [Related]
3. Alveolar progenitor and stem cells in lung development, renewal and cancer.
Desai TJ; Brownfield DG; Krasnow MA
Nature; 2014 Mar; 507(7491):190-4. PubMed ID: 24499815
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
5. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
Cancer Discov; 2024 Feb; 14(2):308-325. PubMed ID: 37931288
[TBL] [Abstract][Full Text] [Related]
6. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
7. Alveolar progenitor cells and the origin of lung cancer.
Sainz de Aja J; Dost AFM; Kim CF
J Intern Med; 2021 May; 289(5):629-635. PubMed ID: 33340175
[TBL] [Abstract][Full Text] [Related]
8. An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
Han G; Sinjab A; Rahal Z; Lynch AM; Treekitkarnmongkol W; Liu Y; Serrano AG; Feng J; Liang K; Khan K; Lu W; Hernandez SD; Liu Y; Cao X; Dai E; Pei G; Hu J; Abaya C; Gomez-Bolanos LI; Peng F; Chen M; Parra ER; Cascone T; Sepesi B; Moghaddam SJ; Scheet P; Negrao MV; Heymach JV; Li M; Dubinett SM; Stevenson CS; Spira AE; Fujimoto J; Solis LM; Wistuba II; Chen J; Wang L; Kadara H
Nature; 2024 Mar; 627(8004):656-663. PubMed ID: 38418883
[TBL] [Abstract][Full Text] [Related]
9. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
10. EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS
Pribluda A; Daemen A; Lima AN; Wang X; Hafner M; Poon C; Modrusan Z; Katakam AK; Foreman O; Eastham J; Hung J; Haley B; Garcia JT; Jackson EL; Junttila MR
Elife; 2022 Aug; 11():. PubMed ID: 35983994
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
12. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
13. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
14. The ERBB network facilitates KRAS-driven lung tumorigenesis.
Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
[TBL] [Abstract][Full Text] [Related]
15. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation.
Regala RP; Justilien V; Walsh MP; Weems C; Khoor A; Murray NR; Fields AP
PLoS One; 2011; 6(10):e26439. PubMed ID: 22022614
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
20. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
